Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.09 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including oligodendrocyte progenitor cells; strongest in retinal horizontal cells | 0.75 |
| chemistry Open Targets | reachable by antibody | 0.36 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 3092
Sealed predictions
- RHBDL3 in dopamine neurons, braak-0.37 (p 0.321) → -0.48 (p 0.194)receipt 3099
- RHBDL3 in oligodendrocytes, braak-0.19 (p 0.631) → -0.55 (p 0.127)receipt 3098
Swarm cases
receipt 3099: RHBDL3 in dopamine neurons, braak
- power
- full sample -0.52 (p 0.026, n 18), 95% CI -0.80 to -0.07. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: -0.54 (p 0.020, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.57 (p 0.014, n 18). not the mix.
- skeptic
- leave-one-out range -0.67 to -0.46, sign flips 0; without severely affected donors -0.52 (p 0.026, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for RHBDL3 in dopamine neurons.
case closed: nothing better to follow up.
receipt 3098: RHBDL3 in oligodendrocytes, braak
- power
- full sample -0.33 (p 0.185, n 18), 95% CI -0.69 to +0.16. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.32 (p 0.191, n 18). does not hold up.
- composition
- oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.39 (p 0.114, n 18). could be the mix.
- skeptic
- leave-one-out range -0.49 to -0.25, sign flips 0; without severely affected donors -0.33 (p 0.185, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for RHBDL3 in oligodendrocytes.
case closed: nothing better to follow up.
Receipts
loading the receipts